Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Restructuring Costs (2022 - 2024)

Akebia Therapeutics has reported Restructuring Costs over the past 3 years, most recently at $58000.0 for Q1 2024.

  • Quarterly Restructuring Costs fell 45.28% to $58000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $58000.0 through Dec 2024, down 67.96% year-over-year, with the annual reading at $58000.0 for FY2024, 67.96% down from the prior year.
  • Restructuring Costs was $58000.0 for Q1 2024 at Akebia Therapeutics, down from $169000.0 in the prior quarter.
  • Over five years, Restructuring Costs peaked at $14.5 million in Q2 2022 and troughed at -$94000.0 in Q2 2023.
  • The 3-year median for Restructuring Costs is $169000.0 (2023), against an average of $2.3 million.
  • The largest YoY upside for Restructuring Costs was 6.11% in 2023 against a maximum downside of 100.65% in 2023.
  • A 3-year view of Restructuring Costs shows it stood at $1.2 million in 2022, then crashed by 86.17% to $169000.0 in 2023, then tumbled by 65.68% to $58000.0 in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Restructuring Costs are $58000.0 (Q1 2024), $169000.0 (Q3 2023), and -$94000.0 (Q2 2023).